Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab.
|NCPE Rapid Review Process||Complete|
|Rapid Review Comissioned||08/08/2017|
|Rapid Review Completed||09/10/2017|
|Outcome||Full pharmacoeconomic assessment recommended|